Marsh & McLennan Reports Solid 2025 Results, Boosts Share Repurchase Program to $6 Billion
summarizeSummary
Marsh & McLennan Companies, Inc. filed its annual 10-K, reporting solid 2025 financial results with 10% revenue growth and a 3% increase in diluted EPS, alongside a significant new $6 billion share repurchase authorization and increased dividends.
check_boxKey Events
-
Solid 2025 Financial Performance
The company reported consolidated revenue of $27.0 billion, a 10% increase (4% underlying), and diluted EPS of $8.43, up 3% from the prior year.
-
New $6 Billion Share Repurchase Authorization
The Board of Directors authorized a new $6 billion share repurchase program in November 2025, superseding prior authorizations, with $2.0 billion in shares repurchased during 2025.
-
Increased Quarterly Dividend
A quarterly dividend of $0.900 per share was declared in January 2026, an increase from the $3.43 per share paid in 2025.
-
Launch of 'Thrive' Restructuring Program
A new three-year 'Thrive' program was launched in Q3 2025, expected to incur $500 million in costs for an estimated $400 million in annualized savings.
auto_awesomeAnalysis
The 10-K filing confirms Marsh & McLennan's solid financial performance for 2025, with a 10% increase in GAAP revenue and a 3% rise in diluted earnings per share. This follows the preliminary results announced in a recent 8-K filing. The company's commitment to shareholder returns is a significant highlight, with a new $6 billion share repurchase authorization, representing a substantial portion of its market capitalization, and an increased quarterly dividend to $0.90 per share. These capital allocation decisions are particularly notable given the stock is currently trading near its 52-week low, signaling strong management confidence in the company's valuation and future prospects. Additionally, the launch of the "Thrive" program, targeting $400 million in annualized savings through efficiency improvements, indicates a proactive approach to enhancing future profitability.
At the time of this filing, MRSH was trading at $171.14 on NYSE in the Finance sector, with a market capitalization of approximately $83.8B. The 52-week trading range was $170.78 to $248.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.